Abstract
Lobectomy via video-assisted thoracoscopic surgery (VATS) has a lower rate of morbidity and is less immunosuppressive than open lobectomy. Compared with open lobectomy, VATS lobectomy appears to have equivalent oncological results. We review the literature on perioperative outcomes, biological impact, and oncological results. Most published reports to date--although retrospective--suggest significant perioperative advantages to VATS lobectomy over open lobectomy. Data on acute phase reactants and cellular immunity show that VATS lobectomy causes less of an inflammatory response and is less immunosuppressive than open lobectomy. Mid- to long-term oncological results of patients with early-stage non-small cell lung cancer (NSCLC) appear to be equivalent for VATS and open lobectomy. Clinical evidence indicates that VATS lobectomy for early-stage NSCLC is associated with fewer postoperative complications and less negative biological impact than open lobectomy. Furthermore, all data to date strongly suggest oncological equivalence between VATS and open lobectomy for patients with early-stage NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
